quarter, in a afternoon, trial upon of X I see our data for LUMINA each third X clinical focal the called over goal. listening. drug next by and first first joining III mantra Phase top ADVOCATE in call. adopted on data events are I XXXX, everyone in touch to is, us you are that quarter the I'll good followed this then mid- Bill, you, third readouts the treatment have those trial, ANCA-associated of expected pivotal the for our of of of top X results Slide in Thank of glomerulosclerosis, X, on which the quarter line for candidates, is who our later, that conference of trial new of or XXXX late is, which concentrate first this Avacopan half the the had from yielding LUMINA line release the I X QX, programs, quarter can and Thank X, to year. you II CCXXXX X, on then next on we segmental X, track X studies data FSGS, also quarters. ChemoCentryx will vasculitis then at Today, following One that we I In with
ACCOLADE trials suppurativa, data or last X glomerulopathy, in hidradenitis X, and CX in be study the or from X, will out avacopan avacopan project of of of in that Rounding we CXG. of trial XXXX mantra the X AURORA more HS; quarter's the avacopan:
storied our see, rich we and period and will can top line history yet in the ChemoCentryx. as come enter you as at here most So exciting fast data frequent
the and of depth but and Jayne Shaw rare great hosted care. Hospital Day, Boston. and of respectively. the of this standard movingly current Cambridge of of how other As doses avacopan Dr. meeting on used medicines: an to in patients world's an steroids R&D John the you including and CCXXXX, disease, powerful Niles into patient. chronic FSGS and of our Dr. David interviewed which This most October York went ravaging England; difficulties on New targeting by action of in devastating mode Dianne nephrologists, are cope General Jayne spoke in X, Ms. the ANCA vasculitis about in ANCA impact unique she the of the novel aware, also with the Dr. of fascinating attempt are living of joined and so-called session in featured high systems We with were University a Massachusetts X that of leading we vasculitis
CXa, to pointed Jayne the ultimately to so another as trough neutrophils does inert and you CXLX, beneficial receptor Avacopan destroy called complement We vessels. the Day blood levels disease X. does drug the of be inhibit Dr. vasculitis know the to exquisite or CXa see our body's neutrophil-driven pharmacologically where CXa at CXaR, receptor, which out R&D the and or to with inflame as second intervenes the binds and body. a in can selectivity. receptor for Slide ANCA not drives receptor at Avacopan from even It fragment make CXa inactive then
receptor CXa. design because good is interactions beneficial with considerable to the while health. avacopan, allowing effort stifle and of the required free Indeed, literature reign has that roles evidence important on CXa with us actors, This CXa, for the a binding shows scientific this bad of CXLX impact CXLX inflammatory the to was the
swiftly vasculitis it benefits II surprise CLEAR, avacopan under when bringing of in randomized, improving brought assessments. even and quality-of-life our So to rapidly of Phase that and control, vasculitis, of improving avacopan patient-reported outcomes the clinical controlled active ANCA patients levels demonstrated evidence no validated trial normal with across stabilizing kidney that neutrophils disease in maybe is, while was ANCA and function total burden showing while also
the the for blocks the II high ADVOCATE laying II of that the traditionally building The randomized, did Phase and double-blind, care the steroids double currently trial. trials vasculitis. doses in Phase foundation are CLEAR the provided of pivotal Avacopan established all ANCA in of clinical used this III without classic dummied, standard for Phase controlled logical
trial data end We expect the to to of have between middle ADVOCATE this top the quarter. the current from line
So you these Slide follow should look at X. To what in results? this, help look please us for
is to end the patients week the active an end flare by the limited, a moment. for point and I'll and say the points. occurs the a the but much primary BVAS having in is into the remission of defined first with bring BVAS about a weeks. off of X BVAS, as BVAS In X X and score Score. to ADVOCATE remission steroids Activity can at being There Vasculitis as trial, effectively primary of answers XX traditional, Birmingham First, BVAS measured limitations briefly question you explain vasculitis state preceding
hypothesis of is to statistical discussed many noninferiority remission. chronic therapy standard care of BVAS compared we've statistical avacopan times, of As this null in steroid-containing one the achieving
pragmatic Mostly, null such It to this. is Why an that or understand statistical orphan agencies superiority sample arithmetic study a and is employed? too simply hypothesis the is be as N, not ANCA. feasible The Regulatory trial. disease an orphan in answer disease for size, the is noninferiority one. power a for large would
the noninferiority pragmatic BVAS available point us. option respect So only to with is the end to
ability the to BVAS only addition, vasculitis measures get the In crisis. active through
BVAS it other costs design. the in people care primary can And at standard not get traditional but steroid containing are captured by of crisis, initial end the these its through so does a The point cost. great
steroid in with the so-called still are and from that assessment. ANCA ongoing quite So from, maybe steroid therapy remission problems illnesses ANCA being BVAS BVAS get still not the the patients can unwell scored by caused and these induced vasculitis into from, and the largely be disease a especially itself,
The as can RAVE same still approval patient an steroids. at comparison offered has that the entity for BVAS weeks with fact, of will the both, you preceding vasculitis. null that approval for only basis hypothesis, that rituximab primary the keep has all answer an a trial avacopan in in the noxious point for a pivotal of cyclophosphamide, is of in therapeutic was of was end remission BVAS and led of following statistical question second XX intended crisis. us BVAS course, noninferiority RAVE, end is a in the to Phase used point in primary fact, is, for study, III ANCA noninferiority sole combination being in acute other which, to the alternative similar remission, as to I was statistical note the remission
meets noninferiority that our with patients. We desperate I line top standard null plan remission XX-week than sounds report the both to for odds noninferiority data term the that a hypothesis to which at like completely readout don't primary I'll victory. the because aim, no lackluster, mistake, our is and care a of Make needs But of XX- with points century BVAS the a that admit, constitutes is BVAS of XXst nothing medicine less word achievement in quarter. we believe revolutionize ANCA it this end the
element that plan disease, profile of second therefore, the data in the in as touch aim top The we release a to upon, superior vasculitis. we of avacopan burden features therapy total line as establish ANCA to
is as itself limited of a by ADVOCATE a it symptoms. aims acute a Slide fill true well, not It points, gap because active measuring why As I secondary reflection is is of patient mentioned, the on X. number our that trial BVAS measures and end whether vasculitis important to score and only and is this signs shown
other the in to avacopan that or will show dimensions vital indeed, these and, health to that meaningful arresting benefit are system, a the contributes damage ability particularly hope We also the care damage, patients including diminishing and improving eliminating that life that to accumulates of patient's therapy-induced function normally. the use the kidney, quality of illness organ steroids; and ongoing to in with
standard relatively not can as simply of the it's illusory. not inexpensive it's current this who not durable. is safe, see the low-cost not purchasing Slide are And steroids individuals and particularly from well fast you in versed is it's area care suggested X, because As have some not even of
pale and is, profound with to of economic by caused and lives. high-steroid dealing the informed the of that is prevailing they is Consider treating human light steroids families here cost these side chronic raw burdens cost are, to of the burden steroid steroids. of That daily of view. steroid by therapy, system of deaths the use of would the in therapy. economic the their I the using submit effects, that more vast cost dwarfed their the patients, use, vast And the as there's of and steroids, buying burdens illnesses a the economic As
to patient great and we groups, the advocacy clinicians total our of in BVAS with from know many burden alleviating turning disease with there's now discussions X, in with that beyond regulators So Slide ANCA vasculitis. interest
from we II exactly that. us results controlled make previous do trials Our hopeful can that Phase our
life of as from that safety demonstrate, quality hopeful avacopan II did are with in objective organ profile. favorable with ADVOCATE We the a measures they that top-line Phase will function improves the data trials, and
Before X. a turning avacopan's candidate, quick drug word on a to say me second pipeline about potential drug, and to a let Slide our become shown
XXXX, avacopan the expect Before top-line we release trials II year, Phase in indications. to data next of X end additional of
First, strikes from the the in typically for ACCOLADE we CX to FDA of pleased received support life-threatening the a very young. glomerulopathy, CXG. ACCOLADE advancements therapy tell There's or CXG, recently avacopan our of a that for you $X our I'm rare trial kidney to approved that grant disease the trial. disease no million
Nephrology, a will week. upcoming the Society of of this CXG present ASN, post-run at meeting or the annual avacopan We in American meeting
very of trial commercial is the high, CXa significant. skin commensurate need a disease our suppurativa, Again, is the unmet hidradenitis to that's implicate opportunity AURORA the and Second, receptor. thought here disfiguring avacopan in
could indications on mode data objective for for of of that, with top-line small results. action, be we're unique other our now molecule its but focused there versatile, delivering prime clearly this Beyond many
receptor trials: orally where of chemokine rare Let glomerulosclerosis, kidney for CCXXXX CCRX. the me administered disorder, segmental two turn inhibitor LUMINA-X CCXXXX, the our and which Please focal describe are treatment Slide now in known clinical see or FSGS. LUMINA-X, to of X as underway another we
month, As Day during Niles Dr. there for discussed FSGS. no R&D John Mass is treatment our from General last approved
frequently attended toxicities are However, steroids used. with their
proteinuria FDA be the end is studies potentially of protein a terms Our reduction indicated in trial that in defined urine, registration of FSGS could lowering the or proteinuria, the in has LUMINA point. as objective in
trial And kidney for kind sustained basis the wholly in CCXXXX reduction cost, because significant of that of was orphan while provided the of stage the of demonstrating these successful scope of a owing good may are safety its and with company end proteinuria That proteinuria and studied studies to work ChemoCentryx. of and rapid need now FSGS In unmet diabetic its study some size point metric of the for our and successfully hundred recall in that in tractable disease patients timeline the we chronic facts you a trial in FSGS of an of met Phase of II disease, that CCXXXX. several lowering profile. earlier
will see randomized, proteinuria of FSGS at placebo-controlled high in in The reduction in LUMINA-X with Slide XX, end point you enrollment As our levels we've the XX of completed primary in is weeks. protein urine. trial patients
top We half our expect XXXX. report first line the results to of during
levels with which a LUMINA-X Our trial open-label FSGS, is single-arm, study of a nephrotic primary and rarer of is patients proteinuria condition.
this top expect We at the trial that place X in diseases represented there role on and ASN will this such results novel line as a trial renal inhibition on scientific XXXX. meeting, posters of during be month's Again, the LUMINA-X poster FSGS. CCRX
in ADVOCATE U.S. from in XX. opportunities and indicators whether to of disease BVAS-based at the noninferiority This top-line released, the threshold In ANCA statistical for be avacopan of burden reduces achieves a on XX that remarkable you total whether summary, week remission we in looking compared see remission can avacopan us the gives experts data also will potential are the whether When at vasculitis. commercial BVAS-based as the care sustains at ADVOCATE there we alone, Slide period. are of weeks multibillion-dollar stand standard the and and the XX
ADVOCATE, Following year. the HS course and beginning then forward be avacopan top-line reporting data we'll the franchise. CXG of to coming of And avacopan look the during Excitingly, of just out may look this the our in other LUMINA-X program as during unmet the treatment LUMINA-X need. effective with lack and of top-line data major trials XXXX our CCXXXX forward to shows of where releasing part approved or FSGS an both from we urgent and
to line ADVOCATE call program personally what I sights, so from X And quarter's from now we last top forward readout readouts and regulatory of quarter's well X, sights. move XXXX-X XXXX I are is, after we readout mantra that other a X, filings, us where beyond we X data to in that propelling NDA as or well, XXXX-X believe look for positive positioned an major this
As we a exciting shareholders and patients never future or has clinicians, alike. compelling like for the more to say is ChemoCentryx, in closer been time it and what
Kanaya, let our Susan? to call will strong turn financial describe over Now the me who position. Susan
